The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses.
Hum Vaccin Immunother
; 20(1): 2351675, 2024 Dec 31.
Article
in En
| MEDLINE
| ID: mdl-38835218
ABSTRACT
Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Influenza Vaccines
/
Cost-Benefit Analysis
/
Influenza, Human
Limits:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Humans
/
Middle aged
Language:
En
Journal:
Hum Vaccin Immunother
/
Hum. vaccin. immunother. (Online)
/
Human vaccines & immunotherapeutics (Online)
Year:
2024
Document type:
Article
Affiliation country:
Canadá
Country of publication:
Estados Unidos